Table 2.

Pooled hazard ratios (95% confidence intervals) of coronary heart disease for continuous use of estrogen-plus-progestin therapy versus no hormone therapy use, the Women's Health Initiative randomized trial and the Nurses' Health Study

	Follow-up period
	Overall	≤2 years	>2 years
All women	1.48 (1.02-2.16)	2.06 (1.49-2.86)	1.28 (0.88-1.86)
Years since menopause
< 10	0.66 (0.31-1.42)	1.29 (0.64-2.59)	0.53 (0.23-1.18)
≥ 10	1.86 (1.21-2.85)	2.42 (1.67-3.50)	1.58 (1.03-2.42)
p-value for heterogeneity *	0.021	0.12	0.018
Age at baseline
50-59	1.05 (0.63-1.76)	2.15 (1.21-3.81)	0.92 (0.51-1.67)
≥ 60	1.82 (1.14-2.91)	2.07 (1.40-3.07)	1.45 (0.95-2.21)
p-value for heterogeneity *	0.12	0.92	0.22

^*Wald test for heterogeneity of the stratum-specific hazard ratios